| Literature DB >> 25317702 |
Ana Carolina Urbaczek1, Lívia Carolina de Abreu Ribeiro1, Valdecir Farias Ximenes2, Ana Afonso3, Camila Tita Nogueira1, Wesley Cardoso Generoso4, Juliana Vieira Alberice5, Martina Rudnicki6, Renila Ferrer6, Luiz Marcos da Fonseca1, Paulo Inácio da Costa1.
Abstract
The hepatitis C virus (Entities:
Mesh:
Substances:
Year: 2014 PMID: 25317702 PMCID: PMC4238766 DOI: 10.1590/0074-0276140090
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Fig. 1: produced envelope glycoprotein 2 (E2) recombinant proteins (sodium dodecyl sulfate polyacrylamide gel electrophoresis 12%). Channel 1: molecular weight marker [BenchMarkTM Protein Ladder (10-220 kDa), Invitrogen]; 2: E2B (approximately 63.5 kDa); 3: E2Y (approximately 50 kDa).
Fig. 2: effect of envelope glycoprotein 2 (E2) recombinant proteins on human umbilical vein endothelial cells viability [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay]. Results are expressed as mean and standard deviation of viable cells. The experiments were performed in triplicate. c-: negative control; c+: culture medium RPMI; LPS: lipopolysaccharide (1.0 µg/mL); Sup: culture supernatant Escherichia coli BL21; TNF-α: tumour necrosis factor alpha (10 ng/mL); *: p < 0.05 compared to the negative control; ***: p < 0.001 compared to the negative control.
Fig. 3: cytotoxicity of envelope glycoprotein 2 (E2) proteins on human umbilical vein endothelial cells. Results presented as mean and standard deviation of percentage obtained in the assay. In each run, 30,000 cells were analysed and all experiments were performed in triplicate. c-: negative control; early apoptosis: annexin V stained cells; late apoptosis: cells double-positive for annexin V and propidium iodide (PI); LPS: lipopolysaccharide (1.0 µg/mL); necrosis: cells stained with PI; Sup: culture supernatant Escherichia coli BL21; TNF-α: tumour necrosis factor alpha (10 ng/mL); ***: p < 0.001 compared to the negative control.
Fig. 4: PARP cleavage in recombinant envelope glycoprotein 2 (E2)-induced apoptosis in human umbilical vein endothelial cells. Cells were pre-treated (C, D) or no (A, B) with N-acetylcysteine (NAC) for 1 h and incubated with recombinant E2 proteins, E2Y (A, C) and E2B (B, D) in different concentrations. The experiments were performed in triplicate. Line 2: 7.81 µg/mL; 3: 15.63 µg/mL; 4: 31.25 µg/mL; 5: 62.5 µg/mL; 6: 125 µg/mL; 7: 250 µg/mL; A-D1: lysate of untreated cells; E1: cells without pre-treatment with NAC and treated with tumour necrosis factor alpha (TNF-α); E2: cells pre-treated with NAC and treated with TNF-α; E3: cells without pre-treatment with NAC and treated with lipopolysaccharide (LPS); E4: cells pre-treated with NAC and treated with LPS; F1-4: actin.
Fig. 5: nitric oxide (NO) production by envelope glycoprotein 2 (E2)-stimulated human umbilical vein endothelial cells. Results are expressed as mean and standard deviation of NO produced in µM. The experiments were performed in triplicate. c-: NO spontaneous production, cells and culture medium; LPS: lipopolysaccharide (1.0 µg/mL); NAC: N-acetylcysteine; Sup: culture supernatant Escherichia coli BL21; TNF-α: tumour necrosis factor alpha (10 ng/mL); ***: p < 0.001 compared to the negative control.
Fig. 6: hydrogen peroxide production by envelope glycoprotein 2 (E2)-stimulated human umbilical vein endothelial cells. Results presented as mean and standard deviation of the mean fluorescence intensity (MFI). The experiments were performed in triplicate. c-: control fluorescence spontaneous, cells without stimulation; LPS: lipopolysaccharide (1.0 µg/mL); NAC: N-acetylcysteine; Sup: culture supernatant Escherichia coli BL21; TNF-α: tumour necrosis factor alpha (10 ng/mL);***: p < 0.001 in relation to negative control.
Fig. 7: interleukin-8 (IL-8) production by envelope glycoprotein 2 (E2)-stimulated human umbilical vein endothelial cells. Results presented as mean and standard deviation. The experiments were performed in triplicate. c-: cells and medium and phosphate-buffered saline (pH 7.2). LPS: lipopolysaccharide (1.0 µg/mL); Sup: culture supernatant Escherichia coli BL21; TNF-α: tumour necrosis factor alpha (10 ng/mL); ***: p < 0.001 compared to negative control; *: p < 0.05 compared to negative control.
Fig. 8: vascular endothelial growth factor A (VEGF-A) production by envelope glycoprotein 2 (E2)-stimulated human umbilical vein endothelial cells. Results presented as mean and standard deviation. The experiments were performed in triplicate. LPS: lipopolysaccharide (1.0 µg/mL); TNF-α: tumour necrosis factor alpha (10 ng/mL); Sup: culture supernatant Escherichia coli BL21; c-: cells and medium and phosphate-buffered saline (pH 7.2); **: p < 0.01 compared to the negative control; ***: p < 0.001 compared to the negative control.